Purdue Pharma L.p.

Eisai R&d Management Co., Ltd.

Earl F Albone

Jing Li

Daniel A Soltis

Xin Cheng

Utpal Majumder

Keiji Furuuchi

Daniel W Custar

Toshimitsu Uenaka

The present invention provides antibodies, and antigen-binding fragments of antibodies, fusion polypeptides and analogs that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides. The present invention further provides methods of preventing, managing, treating or ameliorating one or more symptoms associated with a CA 125/O772P-related disorder. In particular, the present invention provides methods of preventing, managing, treating, or ameliorating one or more symptoms associated with a cell proliferative disorder, such as cancer, e.g., ovarian cancer. The present invention still further provides methods for diagnosing a CA 125/O772P-related disorder or predisposition to developing such a disorder, as well as methods for identifying antibodies, and antigen-binding fragments of antibodies, that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides.

Antibodies that bind cell-associated CA 125/O772P

Nucleic acid molecules encoding antibodies that bind cell-associated CA 125/O772P

Antibodies that bind cell-associated CA 125/O772P and methods of use thereof

Growing community of inventors

Plymouth Meeting, PA, United States of America

Earl F Albone